This S-3 is a routine resale registration with no new dilution for the company. The overhang from the registered shares (20.2% of shares outstanding as of May 14, 2026) could create near-term selling pressure as institutional investors may reduce positions. Monitor trading volume and any prospectus supplements for actual sales by selling stockholders.
Price Chart
Executive Summary
Climb Bio filed an S-3 registration statement to register 11,587,000 shares of common stock for resale by selling stockholders, consisting of 9,481,000 outstanding shares and 2,106,000 shares issuable upon exercise of pre-funded warrants. The shares were issued in a private placement on April 27, 2026, which raised approximately $110.0 million in gross proceeds. The company will not receive any proceeds from the resale of shares under this prospectus, but may receive the nominal exercise price of the pre-funded warrants if exercised. This is a routine resale registration filed to fulfill contractual obligations under a registration rights agreement, not a new capital raise by the company.
Key Facts
- S-3 registers 11,587,000 shares for resale by selling stockholders (9,481,000 outstanding + 2,106,000 pre-funded warrant shares).
- Shares were issued in a private placement on April 27, 2026, raising approximately $110.0 million in gross proceeds at $9.50 per share.
- Company will not receive any proceeds from the resale of shares under this prospectus.
- Filing is a contractual obligation under a registration rights agreement with selling stockholders.
- As of May 14, 2026, the company had 57,263,023 shares outstanding; the registered shares represent approximately 20.2% of the then-outstanding shares.
- RA Capital Healthcare Fund, L.P. is the largest selling stockholder, offering 2,106,000 shares (all pre-funded warrants).
Financial Impact
No new capital raised by the company; the private placement raised approximately $110.0 million in gross proceeds on April 27, 2026.
Risk Factors
- Potential overhang from up to 11.6M shares registered for resale could pressure the stock price.
- Selling stockholders may sell shares at any time, creating unpredictable supply.
- Pre-funded warrants (2.1M shares) could be exercised and sold, adding to selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-248243 |
| Document: d83073dexfilingfees.htm | 0001193125-26-248243 |
| Document: d83073dex51.htm | 0001193125-26-248243 |
| Document: d83073dex231.htm | 0001193125-26-248243 |
| Document: 0001193125-26-248243-index-headers.html | 0001193125-26-248243 |
| Document: 0001193125-26-248243-index.html | 0001193125-26-248243 |
| Document: 0001193125-26-248243.txt | 0001193125-26-248243 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+1 | — | — |
Oct 23, 2026 3d ago | 8-K | $10.47 | awaiting T+1 | — | $8.81 (−15.85%) |
Oct 23, 2026 3d ago | Press Release | $10.34 | awaiting T+1 | — | $8.81 (−14.80%) |
Sep 22, 2026 4w ago | Institutional Cluster | $14.21 $12.52 | ▼ −11.89% | ▼ −11.17% | $8.81 (−38.00%) |
Sep 3, 2026 7w ago | 8-K | $14.59 $15.52 | ▲ +6.37% | ▲ +6.76% | $8.81 (−39.62%) |
Aug 14, 2026 10w ago | 8-K | $16.33 $17.44 | ▲ +6.80% | ▲ +7.27% | $8.81 (−46.05%) |
Aug 6, 2026 11w ago | 8-K | $14.00 $14.00 | · 0.00% | ▼ −0.61% | $8.81 (−37.07%) |
Jun 30, 2026 16w ago | 144 | $13.29 $12.90 | ▼ −2.93% | ▼ −2.80% | $8.81 (−33.71%) |
Jun 12, 2026 19w ago | 8-K | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $8.81 (+23.32%) |
Jun 12, 2026 19w ago | 424B5 | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $8.81 (+23.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers